ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Endometrial Cancer|Hormone Receptor Positive, HER2 Negative Breast Cancer
Interventions: DRUG: ONC201
Sponsor: National Cancer Institute (NCI)